Conduit Pharmaceuticals INC 8-K filings

CDT Equity Inc. is implementing a 1-for-25 reverse stock split to comply with Nasdaq's bid-price rule, effective September 28, 2026.

CDT Equity Inc. has issued a $2.126 million convertible note and warrants to J.J. Astor & Co. as part of a financing arrangement.

CDT Equity Inc. announced the appointment of James Bligh as CEO, effective August 31, 2026, and reported on the outcomes of its 2026 annual meeting of stockholders, where several key proposals were approved.

CDT Equity Inc. files an amendment to its Form 8-K to include financial statements and pro forma information related to its investment in Sarborg Limited.

CDT Equity Inc. filed an amendment to its Form 8-K to include audited financial statements for Sarborg Limited and pro forma financial information following its investment.

CDT Equity Inc. has amended its loan agreement multiple times, significantly increasing its debt principal and interest rate, while also introducing potential share dilution through convertible notes and warrants.

CDT Equity Inc. has entered into a Securities Purchase Agreement to acquire a 4.76% stake in Sarborg Limited by issuing pre-funded warrants.

CDT Equity Inc. announced the issuance of 32,110 shares of common stock to a service provider for consulting services, utilizing an exemption from registration requirements.

CDT Equity Inc. is implementing a 1-for-10 reverse stock split to maintain compliance with Nasdaq's bid-price rule, effective July 17, 2026.

CDT Equity Inc. has amended its loan agreement and convertible note, delaying the start of weekly installment payments.

CDT Equity Inc. has appointed Carr, Riggs & Ingram, L.L.C. as its new independent registered public accounting firm, replacing CBIZ CPAs P.C.

CDT Equity Inc. has entered into a new $1.46 million loan facility with J.J. Astor & Co. to support working capital while eliminating over $6.3 million in legacy debt obligations.

CDT Equity Inc. has received a Nasdaq deficiency notice due to a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026.

CDT Equity Inc. appointed Ulrik Olsen to its Board of Directors and committees, while Freda Lewis-Hall resigned due to family health reasons, leading to further board leadership adjustments.

CDT Equity Inc. will implement a 1-for-25 reverse stock split effective March 26, 2026, with adjusted trading beginning March 27, 2026, to maintain its Nasdaq listing.

CDT Equity Inc. announced the acquisition of a 20% stake in Sarborg Limited for common stock, pre-funded warrants, and deferred cash, alongside extensions of two significant consulting agreements.

CDT Equity Inc. has entered into a $25 million equity line of credit facility with an institutional investor to fund working capital and general corporate purposes.

CDT Equity Inc. has entered into two consulting agreements to enhance its pre-clinical development and accelerate out-licensing opportunities for its solid-form patent portfolio.

CDT Equity Inc. has sold its subsidiary, Conduit Pharmaceuticals Limited, to a related party for $7 million in equity, aiming to shed ongoing litigation liabilities.

CDT Equity Inc. will implement a 1-for-8 reverse stock split to increase its stock price and facilitate future capital raises.

CDT Equity Inc. announced it will restate its Q1 2025 unaudited financial statements due to an accounting error regarding $0.4 million in milestone payments.

CDT Equity Inc. (formerly Conduit Pharmaceuticals) announces a strategic pivot to a data-driven biotech model, appoints James Bligh as permanent CFO, and secures stockholder approvals for its incentive plan and board.

Conduit Pharmaceuticals Inc. has entered into a joint development agreement with Manoira Corporation, an entity controlled by Conduit's CEO, to evaluate its pharmaceutical compounds AZD1656 and AZD5658 for animal health applications, funded by Manoira in exchange for 154,799 shares of Conduit common stock.

Conduit Pharmaceuticals Inc. has announced August 5, 2025, as the date for its 2025 Annual Meeting of Stockholders, along with new deadlines for shareholder proposals and director nominations.

Conduit Pharmaceuticals will implement a 1-for-15 reverse stock split, effective May 19, 2025, to maintain its Nasdaq listing.

Conduit Pharmaceuticals Inc. stockholders approved a reverse stock split at a special meeting on May 5, 2025, with a ratio ranging from 1-for-2 to 1-for-100, not exceeding 1-for-250 in aggregate.

Conduit Pharmaceuticals Inc. reports the resignation of Marcum LLP as their independent auditor and the engagement of CBIZ CPAs, effective April 25, 2025.

Conduit Pharmaceuticals announces Andrew Regan as the new CEO, succeeding David Tapolczay, who will now lead strategy and licensing, alongside Faith Charles' resignation from the Board.

Conduit Pharmaceuticals expands its collaboration with Sarborg Limited to analyze AstraZeneca assets and issues shares for services rendered.

Conduit Pharmaceuticals announces compliance with Nasdaq's Market Value of Publicly Held Securities and Stockholders Equity standards following a successful fundraising effort and debt conversion.